-
Product Insights
NewNet Present Value Model: Trevi Therapeutics Inc’s Nalbuphine Hydrochloride ER
Empower your strategies with our Net Present Value Model: Trevi Therapeutics Inc's Nalbuphine Hydrochloride ER report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nalbuphine Hydrochloride ER in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nalbuphine Hydrochloride ER in Chronic Cough report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nalbuphine Hydrochloride ER in Chronic Cough Drug Details: Nalbuphine hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nalbuphine Hydrochloride ER in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nalbuphine Hydrochloride ER in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nalbuphine Hydrochloride ER in Idiopathic Pulmonary Fibrosis Drug Details:...
-
Product Insights
Pruritus – Drugs In Development, 2023
Global Markets Direct’s, ‘Pruritus - Drugs In Development, 2023’, provides an overview of the Pruritus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chronic Liver Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Liver Disease - Drugs In Development, 2023’, provides an overview of the Chronic Liver Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Prurigo – Drugs In Development, 2023
Global Markets Direct’s, ‘Prurigo - Drugs In Development, 2023’, provides an overview of the Prurigo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prurigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyskinesia - Drugs In Development, 2023’, provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Cough – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Cough - Drugs In Development, 2023’, provides an overview of the Chronic Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LGK-974 in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LGK-974 in Metastatic Pancreatic Cancer Drug Details: LGK-974 is under development for the treatment of...